-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Supernus Pharmaceuticals, Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from 2016 to 2024.
- Supernus Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$5.48M, a 1160% decline year-over-year.
- Supernus Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was -$20.1M, a 21.7% increase from 2023.
- Supernus Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$25.7M, a 2.32% increase from 2022.
- Supernus Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$26.3M, a 427% decline from 2021.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)